High-dose chloroquine for uncomplicated plasmodium falciparum malaria is well tolerated and causes similar QT interval prolongation as standard-dose chloroquine in children

Antimicrobial Agents and Chemotherapy

Volumn 64, Issue 3, 2020, Pages

  Ursing, Johan ^a,b   Rombo, Lars ^c,d   Eksborg, Staffan ^e   Larson, Lena ^a   Bruvoll, Anita ^a   Tarning, Joel ^f,g   Rodrigues, Amabelia ^a   Kofoed, Poul Erik ^a,h  

^a Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Guinea-Bissau)

^b DANDERYD HOSPITAL   (Sweden)

^c Sormland County Council   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g MAHIDOL UNIVERSITY   (Thailand)

^h KOLDING HOSPITAL   (Denmark)

Author keywords

Cardiac safety; Chloroquine; Guinea Bissau; Pfcrt; Pharmacokinetics; Plasmodium falciparum; Tolerability; Treatment

Indexed keywords

AMOXICILLIN; CHLOROQUINE; COTRIMOXAZOLE; HEMOGLOBIN; PARACETAMOL; ANTIMALARIAL AGENT; CARRIER PROTEIN; PFCRT PROTEIN, PLASMODIUM FALCIPARUM; PROTOZOAL PROTEIN;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CONVULSION; DIARRHEA; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; FEVER; GENE FREQUENCY; HEADACHE; HEART ARRHYTHMIA; HUMAN; MALARIA FALCIPARUM; MALE; MEAN ARTERIAL PRESSURE; PARASITE CLEARANCE; PRIORITY JOURNAL; PRURITUS; QTC INTERVAL; STOMACH PAIN; TREATMENT FAILURE; VOMITING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; ELECTROCARDIOGRAPHY; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; GUINEA-BISSAU; LONG QT SYNDROME; METABOLISM; PARASITE LOAD; PARASITOLOGY; PATHOPHYSIOLOGY; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; TREATMENT OUTCOME;

ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; ELECTROCARDIOGRAPHY; FEMALE; GENE EXPRESSION; GUINEA-BISSAU; HUMANS; LONG QT SYNDROME; MALARIA, FALCIPARUM; MALE; MEMBRANE TRANSPORT PROTEINS; PARASITE LOAD; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; TREATMENT OUTCOME;

EID: 85079888788     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01846-19     Document Type: Article

References (33)

1. World Health Organization. 2015. Guidelines for the treatment of malaria, 5th ed. World Health Organization, Geneva, Switzerland. http://www.who.int/malaria/publications/atoz/9789241549127/en/.
2. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361:455–467. https://doi.org/10.1056/NEJMoa0808859.
3. Ursing J, Rombo L, Bergqvist Y, Rodrigues A, Kofoed PE. 2016. High-dose chloroquine for treatment of chloroquine-resistant Plasmodium falciparum malaria. J Infect Dis 213:1315–1321. https://doi.org/10.1093/infdis/jiv590.
4. Ursing J, Kofoed PE, Rodrigues A, Rombo L, Gil JP. 2007. Plasmodium falciparum genotypes associated with chloroquine and amodiaquine resistance in Guinea-Bissau. Am J Trop Med Hyg 76:844–848. https://doi.org/10.4269/ajtmh.2007.76.844.
5. Summers RL, Dave A, Dolstra TJ, Bellanca S, Marchetti RV, Nash MN, Richards SN, Goh V, Schenk RL, Stein WD, Kirk K, Sanchez CP, Lanzer M, Martin RE. 2014. Diverse mutational pathways converge on saturable chloroquine transport via the malaria parasite’s chloroquine resistance transporter. Proc Natl Acad Sci U S A 111:E1759-67. https://doi.org/10.1073/pnas.1322965111.
6. Martin RE, Marchetti RV, Cowan AI, Howitt SM, Broer S, Kirk K. 2009. Chloroquine transport via the malaria parasite’s chloroquine resistance transporter. Science 325:1680–1682. https://doi.org/10.1126/science.1175667.
7. Ursing J, Kofoed PE, Rodrigues A, Bergqvist Y, Rombo L. 2009. Chloroquine is grossly overdosed and overused but well tolerated in Guinea-Bissau. Antimicrob Agents Chemother 53:180–185. https://doi.org/10.1128/AAC.01111-08.
8. Kofoed PE, Ursing J, Poulsen A, Rodrigues A, Bergquist Y, Aaby P, Rombo L. 2007. Different doses of amodiaquine and chloroquine for treatment of uncomplicated malaria in children in Guinea-Bissau: implications for future treatment recommendations. Trans R Soc Trop Med Hyg 101: 231–238. https://doi.org/10.1016/j.trstmh.2006.05.008.
9. Ursing J, Kofoed P-E, Rodrigues A, Blessborn D, Thoft-Nielsen R, Björkman A, Rombo L. 2011. Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial. J Infect Dis 203:109–116. https://doi.org/10.1093/infdis/jiq001.
10. Kofoed PE, Lopez F, Johansson P, Sandstrom A, Hedegaard K, Aaby P, Rombo L. 2002. Treatment of children with Plasmodium falciparum malaria with chloroquine in Guinea-Bissau. Am J Trop Med Hyg 67: 28–31. https://doi.org/10.4269/ajtmh.2002.67.28.
11. White NJ. 2007. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 7:549–558. https://doi.org/10.1016/S1473-3099(07)70187-1.
12. Wernicke JF, Faries D, Breitung R, Girod D. 2005. QT correction methods in children and adolescents. J Cardiovasc Electrophysiol 16:76–81. https://doi.org/10.1046/j.1540-8167.2005.03520.x.
13. Price RN, Nosten F, White NJ. 1998. Prolongation of the QTc interval in African children treated for falciparum malaria. Am J Trop Med Hyg 59:503. https://doi.org/10.4269/ajtmh.1998.59.503.
14. vn Seidlein L, Jaffar S, Greenwood B. 1997. Prolongation of the QTc interval in African children treated for falciparum malaria. Am J Trop Med Hyg 56:494–497. https://doi.org/10.4269/ajtmh.1997.56.494.
15. Ursing J, Rombo L, Rodrigues A, Aaby P, Kofoed PE. 2014. Malaria transmission in Bissau, Guinea-Bissau between 1995 and 2012: malaria resurgence did not negatively affect mortality. PLoS One 9:e101167. https://doi.org/10.1371/journal.pone.0101167.
16. Ceesay SJ, Casals-Pascual C, Erskine J, Anya SE, Duah NO, Fulford AJ, Sesay SS, Abubakar I, Dunyo S, Sey O, Palmer A, Fofana M, Corrah T, Bojang KA, Whittle HC, Greenwood BM, Conway DJ. 2008. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet 372:1545–1554. https://doi.org/10.1016/S0140-6736(08)61654-2.
17. Canete R, Rivas DE, Escobedo AA, Gonzalez ME, Almirall P, Brito K. 2010. A randomized, controlled, open-label trial evaluating the efficacy and safety of chloroquine in the treatment of giardiasis in children. West Indian Med J 59:607–611.
18. Nosten F, ter Kuile FO, Luxemburger C, Woodrow C, Kyle DE, Chongsuphajaisiddhi T, White NJ. 1993. Cardiac effects of antimalarial treatment with halofantrine. Lancet 341:1054–1056. https://doi.org/10.1016/0140-6736(93)92412-m.
19. Mzayek F, Deng H, Mather FJ, Wasilevich EC, Liu H, Hadi CM, Chansolme DH, Murphy HA, Melek BH, Tenaglia AN, Mushatt DM, Dreisbach AW, Lertora JJ, Krogstad DJ. 2007. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials 2:e6. https://doi.org/10.1371/journal.pctr.0020006.
20. Pukrittayakamee S, Tarning J, Jittamala P, Charunwatthana P, Lawpoolsri S, Lee SJ, Hanpithakpong W, Hanboonkunupakarn B, Day NP, Ashley EA, White NJ. 2014. Pharmacokinetic interactions between primaquine and chloroquine. Antimicrob Agents Chemother 58:3354–3359. https://doi.org/10.1128/AAC.02794-13.
21. Valecha N, Savargaonkar D, Srivastava B, Rao BH, Tripathi SK, Gogtay N, Kochar SK, Kumar NB, Rajadhyaksha GC, Lakhani JD, Solanki BB, Jalali RK, Arora S, Roy A, Saha N, Iyer SS, Sharma P, Anvikar AR. 2016. Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study. Malar J 15:42. https://doi.org/10.1186/s12936-016-1084-1.
22. Yap YG, Camm AJ. 2003. Drug induced QT prolongation and torsades de pointes. Heart 89:1363–1372. https://doi.org/10.1136/heart.89.11.1363.
23. Mytton OT, Ashley EA, Peto L, Price RN, La Y, Hae R, Singhasivanon P, White NJ, Nosten F. 2007. Electrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria. Am J Trop Med Hyg 77:447–450. https://doi.org/10.4269/ajtmh.2007.77.447.
24. Augustijns P, Geusens P, Verbeke N. 1992. Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis. Eur J Clin Pharmacol 42:429 – 433. https://doi.org/10.1007/bf00280130.
25. Ursing J, Rombo L, Rodrigues A, Kofoed PE. 2016. Artemetherlumefantrine versus dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in children aged less than 15 years in Guinea-Bissau - an open-label non-inferiority randomised clinical trial. PLoS One 11:e0161495. https://doi.org/10.1371/journal.pone.0161495.
26. Teuscher F, Gatton ML, Chen N, Peters J, Kyle DE, Cheng Q. 2010. Artemisinin-induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure. J Infect Dis 202: 1362–1368. https://doi.org/10.1086/656476.
27. Thapar MM, Gil JP, Bjorkman A. 2005. In vitro recrudescence of Plasmodium falciparum parasites suppressed to dormant state by atovaquone alone and in combination with proguanil. Trans R Soc Trop Med Hyg 99:62–70. https://doi.org/10.1016/j.trstmh.2004.01.016.
28. Mapaba E, Hellgren U, Landberg-Lindgren A, Rombo L. 1995. Susceptibility of Plasmodium falciparum to quinine in vitro: effects of drug concentrations and time of exposure. Trans R Soc Trop Med Hyg 89: 85–89. https://doi.org/10.1016/0035-9203(95)90671-1.
29. Ursing J, Eksborg S, Rombo L, Bergqvist Y, Blessborn D, Rodrigues A, Kofoed PE. 2014. Chloroquine is grossly under dosed in young children with malaria: implications for drug resistance. PLoS One 9:e86801. https://doi.org/10.1371/journal.pone.0086801.
30. Food and Drug Administration. 2001. Bioanalytical method validation: guidance for industry. U.S. Department of Health and Human Services, Rockville, Maryland.
31. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, Coulibaly D. 2001. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 344:257–263. https://doi.org/10.1056/NEJM200101253440403.
32. World Health Organization. 2007. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. World Health Organization, Geneva, Switzerland.
33. World Health Organization. 2009. Methods for surveillance of antimalarial drug efficacy. World Health Organization, Geneva, Switzerland. http://www.who.int/malaria/publications/atoz/9789241597531/en/.